Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.
about
Molecular pathophysiology of priapism: emerging targetsHydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease miceHydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activationHydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.Globin gene expression in correlation with G protein-related genes during erythroid differentiation.Newer aspects of the pathophysiology of sickle cell disease vaso-occlusion.Topical sodium nitrite for chronic leg ulcers in patients with sickle cell anaemia: a phase 1 dose-finding safety and tolerability trial.Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells.Constitutive nitric oxide synthase activation is a significant route for nitroglycerin-mediated vasodilation.Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell diseaseA systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell diseaseStimulated stromal cells induce gamma-globin gene expression in erythroid cells via nitric oxide production.Anagrelide: 20 years later.Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea.Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.Current strategies for the management of children with sickle cell disease.Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.Critical Reviews: How we treat sickle cell patients with leg ulcers.Nitrergic Mechanisms for Management of Recurrent PriapismHow I treat priapism.Hydroxyurea responsiveness in β-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity.Hydroxyurea stimulates the release of ATP from rabbit erythrocytes through an increase in calcium and nitric oxide production.Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties.Skeletal and myocardial microvascular blood flow in hydroxycarbamide-treated patients with sickle cell disease.Treating sickle cell anaemia with hydroxycarbamide.Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia.Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia.Angiogenic factors are increased in circulating granulocytes and CD34+ cells of myeloproliferative neoplasms.Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.Quantification of HBG mRNA in primary erythroid cultures: prediction of the response to hydroxyurea in sickle cell and beta-thalassemia.Sickle Cell DiseaseDecreased nitrite reductase activity of deoxyhemoglobin correlates with platelet activation in hemoglobin E/ß-thalassemia subjects
P2860
Q27010069-53E538E8-F6CE-480C-9213-4668003A0BF1Q30525565-B1A4DD89-808F-4064-AF0F-4FB3127C95D3Q33676406-1ABA7E21-BF90-4749-ACB6-880C5B3EBE38Q34095672-8CB1FECB-ABF6-4449-8E34-D9610BF145F0Q34593268-8B16122C-B5B8-45B2-8575-91EC139413B0Q34941213-475B6900-E364-4F6B-BAC1-7AE5577556D0Q35557934-06A5EDE5-8E62-4AB1-96E1-F5B5A29CB4AFQ36407169-4C204F2B-6513-4C7D-9E7C-CAF0DFD90497Q36735172-A6FF796B-09D6-4AFC-A86A-A307EC5242B8Q36777717-4A130D65-D8E2-48BA-9B02-1E2619134710Q36792555-EF64C1A7-91EB-462B-A570-D2EACFC8460AQ37356342-9A1595B9-7C61-4CA1-9261-161B1A1A534BQ37357291-38B9838F-3302-4442-B80D-55603F13C084Q37397152-71364BCF-6AD8-4C49-8AD7-734B286F2400Q37427980-51BC7168-222E-4926-9A6F-AE2765A0F103Q37810082-47B17A6D-8CF5-4790-BD3F-6C95C3216423Q38211494-A0B180AE-D89A-4930-98A7-A91C8343E85DQ38563567-6A348D2B-D186-4687-83ED-72DE7C801E4FQ38610620-0BD1053A-0B9F-43D8-9AC5-CF80FED88299Q39025090-EF740DE2-026C-4BCB-B436-3A4B0122BC55Q40245190-D52C4ECE-D9B3-4740-B1F2-9E0BD4126874Q40506406-33F8D9BE-14F5-41F2-A8CC-8DEFC7E06886Q42508588-D8151474-D084-4BF2-9D66-F335844D3EB8Q42514544-F6A0E60E-65DA-45CE-9B19-CE7ED611C370Q44076004-E0A1F43E-5EA0-49E3-BFEF-89DBFADE71A9Q44416118-0929A634-B3EE-4419-A871-DBBD83299B22Q47799282-3A117320-D53D-4836-BF34-FEEA230719C4Q50883085-9ACFA6A7-674B-402A-B727-A29BE4BB4213Q51683675-365EC1E1-A874-4967-9042-B623A63C447FQ53153263-0FA13F38-EA5B-4B75-8825-0C25FC219B7DQ54791501-551CC0D0-5C30-48F0-8CDA-A9B5FD9BC12DQ57629590-3DA314BB-CBEB-44E0-8400-F7F5C0DA44ABQ58713620-5E949112-3065-4E14-9B25-C73BB69D2FCE
P2860
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.
@en
type
label
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.
@en
prefLabel
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells.
@en
P2093
P1433
P1476
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
@en
P2093
Bojana B Beleslin-Cokic
Constance T Noguchi
Melanija Tomic
Stanko S Stojilkovic
P304
P356
10.1182/BLOOD-2005-11-4454
P407
P577
2006-03-09T00:00:00Z